

# UKINETS bitesize guidance for the Management of Duodenal Neuroendocrine Tumours

## ***Endoscopic assessment:***

- Record site, size and macroscopic appearance of lesion
- Biopsies for:
  - Histopathological diagnosis
  - Evaluation of proliferative indices (Ki67 index and / or mitotic count)
- Consider EUS if > 10mm for assessment of depth of invasion and local nodal involvement

## ***Imaging:***

- Contrast-enhanced thoracoabdominal CT (with water-load)
- Consider liver MRI
- Functional imaging if nodal / distant metastases suspected


## ***Laboratory analysis:***

- Fasting gut hormone profile
- Consider screening for genetic syndromes (including MEN-I and NF1)

## ***“High-risk features”***

- Functional tumours
- Tumour > 10 mm
- Local nodal disease
- “Deep invasion” (beyond submucosa)
- High grade 2 (Ki67 > 10%) and grade 3 tumours

# UKINETS bitesize guidance for the Management of Duodenal Neuroendocrine Tumours



## UKINETS bitesize guidance for the Management of Duodenal Neuroendocrine Tumours

- Panzuto F, Ramage J, Pritchard DM, van Velthuysen MF, Schrader J, Begum N, Sundin A, Falconi M, O'Toole D. European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for gastroduodenal neuroendocrine tumours (NETs) G1-G3. *J Neuroendocrinol.* 2023 Aug;35(8):e13306. doi: 10.1111/jne.13306. Epub 2023 Jul 4. PMID: 37401795.